How to Manage and Monitor Cardiac Dysfunction in Patients With Metastatic HER2-Positive Breast Cancer
JACC CardioOncol
.
2022 Sep 20;4(3):404-408.
doi: 10.1016/j.jaccao.2022.06.002.
eCollection 2022 Sep.
Authors
Susan F Dent
1
,
Heather Moore
1
,
Priyanka Raval
2
3
,
Laura Alder
1
,
Avirup Guha
3
4
Affiliations
1
Duke Cancer Institute, Duke University, Durham, North Carolina, USA.
2
Division of Hematology and Oncology, Department of Medicine, Medical College of Georgia at Augusta University, Augusta, Georgia, USA.
3
Cardio-Oncology Program, Georgia Cancer Center, Medical College of Georgia at Augusta University, Augusta, Georgia, USA.
4
Division of Cardiology, Department of Medicine, Medical College of Georgia at Augusta University, Augusta, Georgia, USA.
PMID:
36213363
PMCID:
PMC9537063
DOI:
10.1016/j.jaccao.2022.06.002
No abstract available
Keywords:
cardiac monitoring; cardiotoxicity; metastatic breast cancer; novel HER2 agents.
Publication types
Review